Search PubMed⌕ Search

Biomedical subjects

T C Spoor

Publications and source records attributed to T C Spoor.

At least 19 recordsLinked to original sources
PubMed1996

Subtenon's local anesthesia for optic nerve sheath fenestration.

PURPOSE: We used subtenon's local anesthesia for optic nerve sheath fenestration as an alternative to either general or retrobulbar anesthesia. METHODS: Thirty patients with pseudotumor cerebri, who were unresponsive to medical treatment, underwent optic nerve sheath fenestration after administration of topical and subtenon's local anesthesia. RESULTS: When topical tetracaine, in conjunction with subtenon's anesthesia, was administered at the beginning of the procedure, excellent anesthesia and maximal patient comfort were achieved. CONCLUSIONS: The use of local anesthesia allows for a pain-free, expeditious operation with fewer potential anesthetic complications.

Anesthesia, Local↗
PubMed1993

Long-term effectiveness of optic nerve sheath decompression for pseudotumor cerebri.

OBJECTIVE: To determine the long-term success of optic nerve sheath decompression in preserving visual function in patients with pseudotumor cerebri (PTC). DESIGN: To define stability of visual fields, we reviewed 32 series of postoperative visual fields in patients who were undergoing optic nerve sheath decompression for PTC who had stable visual acuity and four or more fields during 6 to 60 months of follow-up. The SD of these series was 0.80 dB (+/- 0.39 dB) of mean deviation. Fluctuations within 2 SDs of the 1-month postoperative field were +/- -1.60 dB. We therefore defined stability as a mean deviation within 2 dB of the preoperative visual field; improvement, greater than 2-dB mean deviation, and worsening, less than 2-dB mean deviation. We then extended our review to include all patients (54 patients, 75 eyes) who underwent optic nerve sheath decompression for PTC, who were followed up with serial automated perimetry (Humphrey 30-2). RESULTS: Fifty-one eyes (68%) showed improvement (36%) or stabilization (32%) of visual function. Twenty-four eyes (32%) experienced deterioration of visual function after an initially successful optic nerve sheath decompression. The probability of failure from 3 to 5 years was .35 by life-table analysis. CONCLUSION: Optic nerve sheath decompression effectively stabilizes or improves visual function in the majority of patients with PTC and visual loss. However, it may fail at any time after surgery. Patients with PTC need to be followed up routinely with automated perimetry to detect deterioration of visual function.

Adolescent↗
PubMed1993

Progressive and static nonarteritic ischemic optic neuropathy treated by optic nerve sheath decompression.

PURPOSE: Optic nerve sheath fenestration has been advocated as an effective treatment for progressive nonarteritic ischemic optic neuropathy (NAION) and anecdotally effective for selected patients with NAION who have not had progressive visual loss. To determine whether optic nerve sheath decompression is of any benefit in patients with NAION, the authors reviewed their experience, surgically treating 23 patients with progressive NAION and 15 patients with static or nonprogressive NAION. RESULTS: Patients with progressive NAION had a significant improvement in visual function as measured by Snellen visual acuity after optic nerve sheath decompression (P = 0.0005). There was no statistically significant improvement in visual field mean deviation (P = 0.11). The 15 patients undergoing optic nerve sheath decompression for static NAION failed to demonstrate significant improvement in either visual acuity (P = 0.90) or visual field mean deviation (P = 0.87). Preoperative standardized echography was used to measure the optic nerve sheath diameter and ascertain its compressibility (30 degrees test). There was a significant difference in compressibility between eyes with static NAION and eyes with progressive NAION (P = 0.001). Accumulation of optic nerve sheath fluid was documented in three eyes initially presenting with NAION and then with development of progressive visual dysfunction. CONCLUSION: Optic nerve sheath decompression improves visual acuity but has little effect on overall visual function in patients with progressive NAION. Optic nerve sheath decompression does not improve visual field or acuity in patients with static NAION. Detection of significant intrasheath fluid by standardized echography helps to objectively differentiate patients with NAION who may benefit from optic nerve sheath decompression.

Adult↗
PubMed1992

Visual field defects in patients with normal-tension glaucoma and patients with high-tension glaucoma.

We compared the automated visual field test results of 24 patients with normal-tension glaucoma and 24 patients with high-tension glaucoma who were closely matched for the amount of visual field loss to determine any differences in the characteristics of visual field defects between the two groups. Patients were matched with a maximum allowable difference in mean deviation of 0.3 dB. Although the normal-tension group had a greater amount of focal visual field loss (pattern standard deviation), the difference was not statistically significant (P = .628). Additionally, there was no statistically significant difference in the amount of diffuse or focal visual field damage in the superior hemifields between the two groups; however, the patients with normal-tension glaucoma had a significantly greater amount of localized visual field loss in the inferior hemifield than the patients with high-tension glaucoma (P = .015). Our data support the hypothesis that a vascular mechanism may have a greater role in the pathogenesis of optic nerve damage and visual field loss in patients with normal-tension glaucoma than in patients with high-tension glaucoma.

Aged↗
PubMed1992

Quantitative evaluation of optic disc pallor in pseudotumor cerebri patients.

We quantified optic disc pallor in patients with pseudotumor cerebri with the Rodenstock Optic Nerve Head Analyzer before and after optic nerve sheath decompression. Mean frequency distribution of pallor peaked between the pallor values of 0.10 and 0.20 in four pseudotumor cerebri patients and between 0.50 and 0.60 in five normal subjects. The red dominant pallor reflectance in pseudotumor cerebri patients decreased significantly and shifted toward the reflectance of normal subjects gradually during the 9 weeks after successful optic nerve sheath decompression, coinciding with the ophthalmoscopic resolution of papilledema. The computerized pallor measurement with the Rodenstock Optic Nerve Head Analyzer allows an objective and quantitative assessment of papilledema in pseudotumor cerebri patients.

Adult↗
PubMed1991

Treatment of pseudotumor cerebri by primary and secondary optic nerve sheath decompression.

We performed optic nerve sheath decompression in 53 patients (101 eyes) with pseudotumor cerebri and visual loss. Sixty-nine eyes (85 patients) with acute papilledema uniformly had improved visual function after optic nerve sheath decompression. Of 32 eyes with chronic papilledema (18 patients), only ten had improved visual function after optic nerve sheath decompression. This difference was significant (P = .0001). Thirteen eyes required secondary or tertiary optic nerve sheath decompression after an initial successful result. Eleven of 13 eyes had improved visual function after repeat optic nerve sheath decompression. We believe that patients with acute papilledema and visual loss should be offered optic nerve sheath decompression, and if symptoms recur, repeat optic nerve sheath decompression is a safe and effective treatment option.

Acute Disease↗
PubMed1991

Optic nerve sheath decompression for the treatment of progressive nonarteritic ischemic optic neuropathy.

We performed optic nerve sheath decompression on four patients (five eyes) with visual loss secondary to nonarteritic anterior ischemic optic neuropathy. Four of the five eyes had marked improvement in visual function after the operation. Optic nerve sheath decompression is an effective treatment for patients with nonarteritic ischemic optic neuropathy and progressive visual loss.

Aged↗
PubMed1990

Treatment of traumatic optic neuropathy with corticosteroids.

We treated 21 patients (22 eyes) with traumatic optic neuropathy by using intravenous megadose methylprednisolone (13 patients) or high-dose dexamethasone (eight patients). Of 13 patients treated with megadose methylprednisolone, 12 had improved visual function, as did seven of nine eyes treated with intravenous dexamethasone. This difference was not significant (P = .3). Initial total blindness, mechanism of injury, or time from injury to treatment did not correlate with visual improvement.

Adolescent↗